Phase I trial of 40-kd branched Pegylated interferon alfa-2a for patients with advanced renal cell carcinomaMOTZER, Robert J; RAKHIT, Ashok; GINSBERG, Michelle et al.Journal of clinical oncology. 2001, Vol 19, Num 5, pp 1312-1319, issn 0732-183XArticle

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerLU, Jian-Feng; EPPLER, Steve M; WOLF, Julie et al.Clinical pharmacology and therapeutics. 2006, Vol 80, Num 2, pp 136-145, issn 0009-9236, 10 p.Article

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2awith and without cytarabine in patients with chronic myelogenous leukemiaTALPAZ, Moshe; RAKHIT, Ashok; RITTWEGER, Karen et al.Clinical cancer research. 2005, Vol 11, Num 17, pp 6247-6255, issn 1078-0432, 9 p.Article

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics : computer-based simulation (SimCYP™) predicts in vivo metabolic inhibitionRAKHIT, Ashok; PANTZE, Michael P; FETTNER, Scott et al.European journal of clinical pharmacology. 2008, Vol 64, Num 1, pp 31-41, issn 0031-6970, 11 p.Article

Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumorsHANAUSKE, Axel-R; CASSIDY, Jim; SASTRE, Javier et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 523-531, issn 1078-0432, 9 p., 1Article

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer : A dose-escalation studyTWELUES, Chris; TRIGO, José M; JONES, Rob et al.European journal of cancer (1990). 2008, Vol 44, Num 3, pp 419-426, issn 0959-8049, 8 p.Article

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteersJIE LING; JOHNSON, Kim A; ZHUANG MIAO et al.Drug metabolism and disposition. 2006, Vol 34, Num 3, pp 420-426, issn 0090-9556, 7 p.Article

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsHAMILTON, Marta; WOLF, Julie L; DROLET, Daniel W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 613-621, issn 0344-5704, 9 p.Article